Peptidomimetic small molecules disrupt type IV secretion system activity in diverse bacterial pathogens

mBio

Volumn 7, Issue 2, 2016, Pages

  Shaffer, Carrie L ^a   Good, James A D ^b   Kumar, Santosh ^c   Syam Krishnan, K ^b,e   Gaddy, Jennifer A ^a,d   Loh, John T ^a   Chappell, Joseph ^c   Almqvist, Fredrik ^b   Cover, Timothy L ^a,d   Hadjifrangiskou, Maria ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UMEÅ UNIVERSITY   (Sweden)

^c UNIVERSITY OF KENTUCKY   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e University of Kerala   (India)

Author keywords

[No Author keywords available]

Indexed keywords

C 10; CAGA PROTEIN; DIMETHYL SULFOXIDE; GKP 42; KSK 85; PEPTIDE; PEPTIDOGLYCAN; PEPTIDOMIMETIC AGENT; UNCLASSIFIED DRUG; BACTERIAL PROTEIN; MOLECULAR LIBRARY; TYPE IV SECRETION SYSTEM;

AGROBACTERIUM TUMEFACIENS; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL PLANT DISEASE; BACTERIUM PILUS; BIOGENESIS; CONTROLLED STUDY; DNA TRANSFER; DRUG STRUCTURE; EPITHELIUM CELL; ESCHERICHIA COLI; GENE TARGETING; HELICOBACTER PYLORI; HOST CELL; HUMAN; HUMAN CELL; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN TRANSPORT; STOMACH EPITHELIUM; TYPE IV SECRETION SYSTEM; DRUG EFFECTS; GENETICS; HELICOBACTER INFECTION; METABOLISM; MICROBIOLOGY; MOLECULAR LIBRARY; PHARMACOLOGY; PLANT DISEASE;

AGROBACTERIUM TUMEFACIENS; BACTERIAL PROTEINS; ESCHERICHIA COLI; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PEPTIDOMIMETICS; PLANT DISEASES; PROTEIN TRANSPORT; SMALL MOLECULE LIBRARIES; TYPE IV SECRETION SYSTEMS;

EID: 84965144210     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00221-16     Document Type: Article

References (59)

1. Cascales E, Christie PJ. 2003. The versatile bacterial type IV secretion systems. Nat Rev Microbiol 1:137–149. http://dx.doi.org/10.1038/nrmicro753.
2. Alvarez-Martinez CE, Christie PJ. 2009. Biological diversity of prokaryotic type IV secretion systems. Microbiol Mol Biol Rev 73:775–808. http://dx.doi.org/10.1128/MMBR.00023-09.
3. Fronzes R, Christie PJ, Waksman G. 2009. The structural biology of type IV secretion systems. Nat Rev Microbiol 7:703–714. http://dx.doi.org/10.1038/nrmicro2218.
4. Christie PJ, Atmakuri K, Krishnamoorthy V, Jakubowski S, Cascales E. 2005. Biogenesis, architecture, and function of bacterial type IV secretion systems. Annu Rev Microbiol 59:451-485. http://dx.doi.org/10.1146/annurev.micro.58.030603.123630.
5. Yeo HJ, Waksman G. 2004. Unveiling molecular scaffolds of the type IV secretion system. J Bacteriol 186:1919–1926. http://dx.doi.org/10.1128/JB.186.7.1919-1926.2004.
6. Rivera-Calzada A, Fronzes R, Savva CG, Chandran V, Lian PW, Laeremans T, Pardon E, Steyaert J, Remaut H, Waksman G, Orlova EV. 2013. Structure of a bacterial type IV secretion core complex at subnanometre resolution. EMBO J 32:1195–1204. http://dx.doi.org/10.1038/emboj.2013.58.
7. Low HH, Gubellini F, Rivera-Calzada A, Braun N, Connery S, Dujean-court A, Lu F, Redzej A, Fronzes R, Orlova EV, Waksman G. 2014. Structure of a type IV secretion system. Nature 508:550-553. http://dx.doi.org/10.1038/nature13081.
8. Cascales E, Christie PJ. 2004. Definition of a bacterial type IV secretion pathway for a DNA substrate. Science 304:1170–1173. http://dx.doi.org/10.1126/science.1095211.
9. Fronzes R, Schäfer E, Wang L, Saibil HR, Orlova EV, Waksman G. 2009. Structure of a type IV secretion system core complex. Science 323: 266–268. http://dx.doi.org/10.1126/science.1166101.
10. Bourzac KM, Guillemin K. 2005. Helicobacter pylori-host cell interactions mediated by type IV secretion. Cell Microbiol 7:911–919. http://dx.doi.org/10.1111/j.1462-5822.2005.00541.x.
11. Tegtmeyer N, Wessler S, Backert S. 2011. Role of the cag-pathogenicity island encoded type IV secretion system in Helicobacter pylori pathogenesis. FEBS J 278:1190-1202. http://dx.doi.org/10.1111/j.1742-4658.2011.08035.x.
12. Odenbreit S, Püls J, Sedlmaier B, Gerland E, Fischer W, Haas R. 2000. Translocation of Helicobacter pylori CagA into gastric epithelial cells by type IV secretion. Science 287:1497–1500. http://dx.doi.org/10.1126/science.287.5457.1497.
13. Cover TL, Blaser MJ. 2009. Helicobacter pylori in health and disease. Gastroenterology 136:1863–1873. http://dx.doi.org/10.1053/j.gastro.2009.01.073.
14. Fischer W. 2011. Assembly and molecular mode of action of the Helicobacter pylori Cag type IV secretion apparatus. FEBS J 278:1203–1212. http://dx.doi.org/10.1111/j.1742-4658.2011.08036.x.
15. Viala J, Chaput C, Boneca IG, Cardona A, Girardin SE, Moran AP, Athman R, Mémet S, Huerre MR, Coyle AJ, DiStefano PS, Sansonetti PJ, Labigne A, Bertin J, Philpott DJ, Ferrero RL. 2004. Nod1 responds to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island. Nat Immunol 5:1166–1174. http://dx.doi.org/10.1038/ni1131.
16. Brandt S, Kwok T, Hartig R, König W, Backert S. 2005. NF-kappaB activation and potentiation of proinflammatory responses by the Helicobacter pylori CagA protein. Proc Natl Acad Sci U S A 102:9300–9305. http://dx.doi.org/10.1073/pnas.0409873102.
17. Lamb A, Yang XD, Tsang YH, Li JD, Higashi H, Hatakeyama M, Peek RM, Blanke SR, Chen LF. 2009. Helicobacter pylori CagA activates NFkappaB by targeting TAK1 for TRAF6-mediated Lys 63 ubiquitination. EMBO Rep 10:1242–1249. http://dx.doi.org/10.1038/embor.2009.210.
18. Guillemin K, Salama NR, Tompkins LS, Falkow S. 2002. Cag pathogenicity island-specific responses of gastric epithelial cells to Helicobacter pylori infection. Proc Natl Acad Sci U S A 99:15136-15141. http://dx.doi.org/10.1073/pnas.182558799.
19. Johnson EM, Gaddy JA, Voss BJ, Hennig EE, Cover TL. 2014. Genes required for assembly of pili associated with the Helicobacter pylori cag type IV secretion system. Infect Immun 82:3457–3470. http://dx.doi.org/10.1128/iai.01640-14.
20. Shaffer CL, Gaddy JA, Loh JT, Johnson EM, Hill S, Hennig EE, McClain MS, McDonald WH, Cover TL. 2011. Helicobacter pylori exploits a unique repertoire of type IV secretion system components for pilus assembly at the bacteria-host cell interface. PLoS Pathog 7:e1002237. http://dx.doi.org/10.1371/journal.ppat.1002237.
21. Barrozo RM, Cooke CL, Hansen LM, Lam AM, Gaddy JA, Johnson EM, Cariaga TA, Suarez G, Peek RM, Jr, Cover TL, Solnick JV. 2013. Functional plasticity in the type IV secretion system of Helicobacter pylori. PLoS Pathog 9: e1003189. http://dx.doi.org/10.137 1/journal.ppat.1003189.
22. Rohde M, Püls J, Buhrdorf R, Fischer W, Haas R. 2003. A novel sheathed surface organelle of the Helicobacter pylori cag type IV secretion system. Mol Microbiol 49:219-234. http://dx.doi.org/10.1046/j.1365-2958.2003.03549.x.
23. Backert S, Fronzes R, Waksman G. 2008. VirB2 and VirB5 proteins: specialized adhesins in bacterial type-IV secretion systems? Trends Microbiol 16:409–413. http://dx.doi.org/10.1016/j.tim.2008.07.001.
24. Jiménez-Soto LF, Kutter S, Sewald X, Ertl C, Weiss E, Kapp U, Rohde M, Pirch T, Jung K, Retta SF, Terradot L, Fischer W, Haas R. 2009. Helicobacter pylori type IV secretion apparatus exploits beta1 integrin in a novel RGD-independent manner. PLoS Pathog 5:e1000684. http://dx.doi.org/10.1371/journal.ppat.1000684.
25. Kwok T, Zabler D, Urman S, Rohde M, Hartig R, Wessler S, Misselwitz R, Berger J, Sewald N, König W, Backert S. 2007. Helicobacter exploits integrin for type IV secretion and kinase activation. Nature 449:862–866. http://dx.doi.org/10.1038/nature06187.
26. Jakubowski SJ, Kerr JE, Garza I, Krishnamoorthy V, Bayliss R, Waksman G, Christie PJ. 2009. Agrobacterium VirB10 domain requirements for type IV secretion and T pilus biogenesis. Mol Microbiol 71:779–794. http://dx.doi.org/10.1111/j.1365-2958.2008.06565.x.
27. Garza I, Christie PJ. 2013. A putative transmembrane leucine zipper of Agrobacterium VirB10 is essential for T-pilus biogenesis but not type IV secretion. J Bacteriol 195:3022–3034. http://dx.doi.org/10.1128/JB.00287-13.
28. Spring DR. 2005. Chemical genetics to chemical genomics: small molecules offer big insights. Chem Soc Rev 34:472-482. http://dx.doi.org/10.1039/b312875j.
29. Smith MA, Coinçon M, Paschos A, Jolicoeur B, Lavallée P, Sygusch J, Baron C. 2012. Identification of the binding site of Brucella VirB8 interaction inhibitors. Chem Biol 19:1041–1048. http://dx.doi.org/10.1016/j.chembiol.2012.07.007.
30. Paschos A, den Hartigh A, Smith MA, Atluri VL, Sivanesan D, Tsolis RM, Baron C. 2011. An in vivo high-throughput screening approach targeting the type IV secretion system component VirB8 identified inhibitors of Brucella abortus 2308 proliferation. Infect Immun 79:1033–1043. http://dx.doi.org/10.1128/IAI.00993-10.
31. Sayer JR, Walldén K, Pesnot T, Campbell F, Gane PJ, Simone M, Koss H, Buelens F, Boyle TP, Selwood DL, Waksman G, Tabor AB. 2014. 2-and 3-substituted imidazo[1,2-a]pyrazines as inhibitors of bacterial type IV secretion. Bioorg Med Chem 22:6459-6470. http://dx.doi.org/10.1016/j.bmc.2014.09.036.
32. Hilleringmann M, Pansegrau W, Doyle M, Kaufman S, MacKichan ML, Gianfaldoni C, Ruggiero P, Covacci A. 2006. Inhibitors of Helicobacter pylori ATPase Cagalpha block CagA transport and cag virulence. Microbiology 152:2919–2930. http://dx.doi.org/10.1099/mic.0.28984-0.
33. Svensson A, Larsson A, Emtenäs H, Hedenström M, Fex T, Hultgren SJ, Pinkner JS, Almqvist F, Kihlberg J. 2001. Design and evaluation of pilicides: potential novel antibacterial agents directed against uropathogenic Escherichia coli. Chembiochem 2:915–918. http://dx.doi.org/10.1002/1439-7633(20011203)2:12_915::AID-CBIC915_3.0.CO;2-M.
34. Emtenäs H, Alderin L, Almqvist F. 2001. An enantioselective ketene_imine cycloaddition method for synthesis of substituted ring-fused 2-pyridinones. J Org Chem 66:6756-6761. http://dx.doi.org/10.1021/jo015794u.
35. Pinkner JS, Remaut H, Buelens F, Miller E, Åberg V, Pemberton N, Hedenström M, Larsson A, Seed P, Waksman G, Hultgren SJ, Almqvist F. 2006. Rationally designed small compounds inhibit pilus biogenesis in uropathogenic bacteria. Proc Natl Acad Sci U S A 103:17897–17902. http://dx.doi.org/10.1073/pnas.0606795103.
36. Chorell E, Pinkner JS, Phan G, Edvinsson S, Buelens F, Remaut H, Waksman G, Hultgren SJ, Almqvist F. 2010. Design and synthesis of C-2 substituted thiazolo and dihydrothiazolo ring-fused 2-pyridones: pilicides with increased antivirulence activity. J Med Chem 53:5690–5695. http://dx.doi.org/10.1021/jm100470t.
37. Cegelski L, Pinkner JS, Hammer ND, Cusumano CK, Hung CS, Chorell E, Åberg V, Walker JN, Seed PC, Almqvist F, Chapman MR, Hultgren SJ. 2009. Small-molecule inhibitors target Escherichia coli amyloid biogenesis and biofilm formation. Nat Chem Biol 5:913–919. http://dx.doi.org/10.1038/nchembio.242.
38. Kim SY, Lee YC, Kim HK, Blaser MJ. 2006. Helicobacter pylori CagA transfection of gastric epithelial cells induces interleukin-8. Cell Microbiol 8:97–106. http://dx.doi.org/10.1111/j.1462-5822.2005.00603.x.
39. Greene SE, Pinkner JS, Chorell E, Dodson KW, Shaffer CL, Conover MS, Livny J, Hadjifrangiskou M, Almqvist F, Hultgren SJ. 2014. Pilicide ec240 disrupts virulence circuits in uropathogenic Escherichia coli. mBio 5:e02038-14. http://dx.doi.org/10.1128/mBio.02038-14.
40. Emtenäs H, Ahlin K, Pinkner JS, Hultgren SJ, Almqvist F. 2002. Design and parallel solid-phase synthesis of ring-fused 2-pyridinones that target pilus biogenesis in pathogenic bacteria. J Comb Chem 4:630–639. http://dx.doi.org/10.1021/cc020032d.
41. Sellstedt M, Almqvist F. 2008. Synthesis of a novel tricyclic peptidomimetic scaffold. Org Lett 10:4005-4007. http://dx.doi.org/10.1021/ol801506y.
42. Sellstedt M, Almqvist F. 2009. A novel heterocyclic scaffold formed by ring expansion of a cyclic sulfone to sulfonamides. Org Lett 11: 5470–5472. http://dx.doi.org/10.1021/ol9023024.
43. Sellstedt M, Almqvist F. 2011. A three-component reaction forming naphthyridones—synthesis of lophocladine analogs. Org Lett 13: 5278–5281. http://dx.doi.org/10.1021/ol202080x.
44. Sellstedt M, Prasad GK, Krishnan SK, Almqvist F. 2012. Directed diversity-oriented synthesis. Ring-fused 5-to 10-membered rings from a common peptidomimetic 2-pyridone precursor. Tetrahedron Lett 53: 6022–6024.
45. Selbach M, Moese S, Meyer TF, Backert S. 2002. Functional analysis of the Helicobacter pylori cag pathogenicity island reveals both VirD4-CagAdependent and VirD4-CagA-independent mechanisms. Infect Immun 70: 665–671. http://dx.doi.org/10.1128/IAI.70.2.665-671.2002.
46. Tan S, Tompkins LS, Amieva MR. 2009. Helicobacter pylori usurps cell polarity to turn the cell surface into a replicative niche. PLoS Pathog 5:e1000407. http://dx.doi.org/10.1371/journal.ppat.1000407.
47. Thanassi DG, Bliska JB, Christie PJ. 2012. Surface organelles assembled by secretion systems of Gram-negative bacteria: diversity in structure and function. FEMS Microbiol Rev 36:1046–1082. http://dx.doi.org/10.1111/j.1574-6976.2012.00342.x.
48. Thomas CL, Leh V, Lederer C, Maule AJ. 2003. Turnip crinkle virus coat protein mediates suppression of RNA silencing in Nicotiana benthamiana. Virology 306:33–41. http://dx.doi.org/10.1016/S0042-6822(02)00018-1.
49. Aguilar J, Zupan J, Cameron TA, Zambryski PC. 2010. Agrobacterium type IV secretion system and its substrates form helical arrays around the circumference of virulence-induced cells. Proc Natl Acad Sci U S A 107: 3758–3763. http://dx.doi.org/10.1073/pnas.0914940107.
50. Getino M, Sanabria-Ríos DJ, Fernández-López R, Campos-Gómez J, Sánchez-López JM, Fernández A, Carballeira NM, de la Cruz F. 2015. Synthetic fatty acids prevent plasmid-mediated horizontal gene transfer. mBio 6:e01032-15. http://dx.doi.org/10.1128/mBio.01032-15.
51. Peek RM, Jr, Blaser MJ. 2002. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2:28-37. http://dx.doi.org/10.1038/nrc703.
52. Kodaman N, Pazos A, Schneider BG, Piazuelo MB, Mera R, Sobota RS, Sicinschi LA, Shaffer CL, Romero-Gallo J, de Sablet T, Harder RH, Bravo LE, Peek RM, Jr, Wilson KT, Cover TL, Williams SM, Correa P. 2014. Human and Helicobacter pylori coevolution shapes the risk of gastric disease. Proc Natl Acad Sci U S A 111:1455–1460. http://dx.doi.org/10.1073/pnas.1318093111.
53. Hatakeyama M. 2004. Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat Rev Cancer 4:688-694. http://dx.doi.org/10.1038/nrc1433.
54. Mueller D, Tegtmeyer N, Brandt S, Yamaoka Y, De Poire E, Sgouras D, Wessler S, Torres J, Smolka A, Backert S. 2012. c-Src and c-Abl kinases control hierarchic phosphorylation and function of the CagA effector protein in Western and East Asian Helicobacter pylori strains. J Clin Invest 122:1553–1566. http://dx.doi.org/10.1172/JCI61143.
55. Blaser MJ. 2005. The biology of cag in the Helicobacter pylori-human interaction. Gastroenterology 128:1512–1515. http://dx.doi.org/10.1053/j.gastro.2005.03.053.
56. Ohnishi N, Yuasa H, Tanaka S, Sawa H, Miura M, Matsui A, Higashi H, Musashi M, Iwabuchi K, Suzuki M, Yamada G, Azuma T, Hatakeyama M. 2008. Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse. Proc Natl Acad Sci U S A 105:1003–1008. http://dx.doi.org/10.1073/pnas.0711183105.
57. Amieva MR, Vogelmann R, Covacci A, Tompkins LS, Nelson WJ, Falkow S. 2003. Disruption of the epithelial apical-junctional complex by Helicobacter pylori CagA. Science 300:1430-1434. http://dx.doi.org/10.1126/science.1081919.
58. Jefferson RA, Kavanagh TA, Bevan MW. 1987. GUS fusions: betaglucuronidase as a sensitive and versatile gene fusion marker in higher plants. EMBO J 6:3901–3907.
59. Wu S, Schoenbeck MA, Greenhagen BT, Takahashi S, Lee S, Coates RM, Chappell J. 2005. Surrogate splicing for functional analysis of sesquiterpene synthase genes. Plant Physiol 138:1322–1333. http://dx.doi.org/10.1104/pp.105. 059386.